series-b
Stage
About
Anokion develops antigen-specific therapies for autoimmune diseases using its proprietary T cell immunotherapy platform to reprogram the immune system.
Explore Anokion's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.